WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 525274
Description: Imazodan hydrochloride is a potent and selective type III phosphodiesterase inhibitor.Imazodan hydrochloride is used for the treatment of chronic congestive heart failure.
MedKoo Cat#: 525274
Name: Imazodan hydrochloride
Chemical Formula: C13H13ClN4O
Molecular Weight: 276.72
Elemental Analysis: C, 56.42; H, 4.74; Cl, 12.81; N, 20.25; O, 5.78
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Imazodan hydrochloride; Imazodan HCl; CI-914; CI 914; CI914; Imazodan hydrochloride [USAN].
IUPAC/Chemical Name: 3(2H)-Pyridazinone, 4,5-dihydro-6-(4-(1H-imidazol-1-yl)phenyl)-, monohydrochloride
InChi Key: BFIMZKOUNDYWCE-UHFFFAOYSA-N
InChi Code: InChI=1S/C13H12N4O.ClH/c18-13-6-5-12(15-16-13)10-1-3-11(4-2-10)17-8-7-14-9-17;/h1-4,7-9H,5-6H2,(H,16,18);1H
SMILES Code: O=C1CCC(C2=CC=C(N3C=CN=C3)C=C2)=NN1.[H]Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 276.72 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Goldberg AD, Nicklas J, Goldstein S. Effectiveness of imazodan for treatment of chronic congestive heart failure. The Imazodan Research Group. Am J Cardiol. 1991 Sep 1;68(6):631-6. PubMed PMID: 1715125.
2: Allert JA, Adams HR. Inotropic and chronotropic profile of MCI-154: comparison with isoproterenol and imazodan in guinea pig cardiac preparations. J Cardiovasc Pharmacol. 1990 Jul;16(1):59-67. PubMed PMID: 1696667.
3: Jiang YY, Long K, Sheng ML. [Effects of imazodan and dazoxiben on cAMP levels and PGI2 production in cultured bovine aortic endothelial cells]. Zhongguo Yao Li Xue Bao. 1989 Sep;10(5):421-4. Chinese. PubMed PMID: 2559580.
4: Weishaar RE, Kobylarz-Singer D, Klinkefus BA. New mechanisms for positive inotropic agents: focus on the discovery and development of imazodan. Cardiovasc Drugs Ther. 1989 Mar;3(1):29-42. Review. PubMed PMID: 2487522.
5: Geria T, Hong WH, Daly RE. High-performance liquid chromatographic assay of imazodan, methylparaben and propylparaben in imazodan injection. J Chromatogr. 1988 Oct 26;450(3):407-13. PubMed PMID: 3241022.
6: Sircar I, Morrison GC, Burke SE, Skeean R, Weishaar RE. Cardiotonic agents. 6. Synthesis and inotropic activity of 2,4-dihydro-5-[4-(1H-imidazol-1-yl)phenyl]-3H-pyrazol-3-ones: ring-contracted analogues of imazodan (CI-914). J Med Chem. 1987 Oct;30(10):1724-8. PubMed PMID: 3656349.
7: Steffen RP, Eldon CM, Evans DB. The effect of the cardiotonic imazodan (CI-914) on myocardial and peripheral hemodynamics in the anesthetized dog. J Cardiovasc Pharmacol. 1986 May-Jun;8(3):520-6. PubMed PMID: 2425167.